PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsGa68
Ga68
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
172 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MeningiomaD008579EFO_0003098D32.933—117
ParagangliomaD010235——43—1—6
MedulloblastomaD008527——13—115
Pituitary neoplasmsD010911————11—2
Olfactory esthesioneuroblastomaD018304EFO_1000407——1—1—2
Central nervous system neoplasmsD016543—————1—1
HemangioblastomaD018325—————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471—C61163013—1968
NeoplasmsD009369—C80684—519
CarcinomaD002277—C80.0751—316
AdenocarcinomaD000230——1102—215
Castration-resistant prostatic neoplasmsD064129——2104——13
RecurrenceD012008——246—211
Lung neoplasmsD008175—C34.90211—25
Positron-emission tomographyD049268——111—13
Diagnostic imagingD003952———11——2
Pituitary diseasesD010900—E23.7——1——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine tumorsD018358EFO_1001901D3A.81810——528
Hepatocellular carcinomaD006528—C22.063——312
Liver neoplasmsD008113EFO_1001513C22.063——211
Neuroendocrine carcinomaD018278——43——28
Breast neoplasmsD001943EFO_0003869C5053——17
Carcinoid tumorD002276—D3A.0054——17
NeuroblastomaD009447EFO_0000621—45———7
Thyroid neoplasmsD013964EFO_0003841—32——16
Pancreatic neoplasmsD010190EFO_0003860C2543———6
Head and neck neoplasmsD006258——41———5
Show 32 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD012509——4———15
Brain neoplasmsD001932EFO_0003833C712———13
CholangiocarcinomaD018281—C22.13————3
Ovarian neoplasmsD010051EFO_0003893C562———13
Esophageal neoplasmsD004938—C153————3
Colorectal neoplasmsD015179——2———13
Solitary fibrous tumorsD054364——1———12
Urologic neoplasmsD014571—C64-C682————2
Urinary bladder neoplasmsD001749—C672————2
Skin neoplasmsD012878EFO_0004198C442————2
Show 35 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_0000515—————22
AstrocytomaD001254EFO_0000271—————22
OligodendrogliomaD009837EFO_0000631—————22
InflammationD007249MP_0001845—————22
Islet cell adenomaD007516EFO_0007331D13.7————11
GliosarcomaD018316——————11
Acoustic neuromaD009464——————11
EpendymomaD004806——————11
Ewing sarcomaD012512EFO_0000173—————11
Choroid plexus neoplasmsD016545EFO_0007206—————11
Show 28 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name—
INN—
Description
—
Classification
Unknown
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL ID—
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use